BR112017008734A2 - acelerador de produção de proteína tau e agente preventivo ou terapêutico e composição alimentícia preventiva ou terapêutica para doenças causadas por deficiência de proteína tau - Google Patents

acelerador de produção de proteína tau e agente preventivo ou terapêutico e composição alimentícia preventiva ou terapêutica para doenças causadas por deficiência de proteína tau

Info

Publication number
BR112017008734A2
BR112017008734A2 BR112017008734-0A BR112017008734A BR112017008734A2 BR 112017008734 A2 BR112017008734 A2 BR 112017008734A2 BR 112017008734 A BR112017008734 A BR 112017008734A BR 112017008734 A2 BR112017008734 A2 BR 112017008734A2
Authority
BR
Brazil
Prior art keywords
tou
protein
preventive
tau protein
medicine
Prior art date
Application number
BR112017008734-0A
Other languages
English (en)
Japanese (ja)
Other versions
BR112017008734B1 (pt
Inventor
Ishii Yoichi
Nemoto Takayuki
Okamoto Takeshi
Original Assignee
Well Stone Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Well Stone Co. filed Critical Well Stone Co.
Publication of BR112017008734A2 publication Critical patent/BR112017008734A2/pt
Publication of BR112017008734B1 publication Critical patent/BR112017008734B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/20—Natural extracts
    • A23V2250/204—Animal extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/10—Preparation or pretreatment of starting material
    • A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

acelerador de produção de proteína tau e agente preventivo ou terapêutico e composição alimentícia preventiva ou terapêutica para doenças causadas por deficiência de proteína tau, sendo um objetivo da presente invenção fornecer um acelerador de produção de proteína tau que contém um produto natural como um ingrediente ativo; um agente preventivo ou terapêutico para uma doença causada por deficiência de proteína tau; e uma composição alimentícia preventiva ou terapêutica para uma doença causada por deficiência de proteína tau, sendo que são fornecidos: um acelerador de produção de proteína tau que contém um pó seco, um produto moído e/ou um extrato de uma minhoca como um ingrediente ativo; um agente preventivo ou terapêutico para uma doença causada por deficiência de proteína tau; e uma composição alimentícia preventiva ou terapêutica para uma doença causada por deficiência de proteína tau, sedno que a doença causada por deficiência de proteína tau é preferencialmente doença de alzheimer.
BR112017008734-0A 2014-11-04 2015-11-02 Acelerador de produção de proteína tau e agente preventivo ou terapêutico e composição alimentícia preventiva ou terapêutica para doenças causadas por deficiência de proteína tau BR112017008734B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014-223977 2014-11-04
JP2014223977A JP6321521B2 (ja) 2014-11-04 2014-11-04 タウ蛋白産生促進剤、タウ蛋白の欠乏に起因する疾患の治療薬・予防薬および治療用・予防用食品組成物
PCT/JP2015/080934 WO2016072392A1 (ja) 2014-11-04 2015-11-02 タウ蛋白産生促進剤、タウ蛋白の欠乏に起因する疾患の治療薬・予防薬および治療用・予防用食品組成物

Publications (2)

Publication Number Publication Date
BR112017008734A2 true BR112017008734A2 (pt) 2018-02-27
BR112017008734B1 BR112017008734B1 (pt) 2021-11-23

Family

ID=55909117

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017008734-0A BR112017008734B1 (pt) 2014-11-04 2015-11-02 Acelerador de produção de proteína tau e agente preventivo ou terapêutico e composição alimentícia preventiva ou terapêutica para doenças causadas por deficiência de proteína tau

Country Status (12)

Country Link
US (2) US10398740B2 (pt)
EP (1) EP3216456B1 (pt)
JP (1) JP6321521B2 (pt)
KR (1) KR101948913B1 (pt)
CN (1) CN106794199B (pt)
AU (1) AU2015344361B2 (pt)
BR (1) BR112017008734B1 (pt)
CA (1) CA2964316C (pt)
PH (1) PH12017500743A1 (pt)
RU (1) RU2742658C2 (pt)
TW (1) TWI689311B (pt)
WO (1) WO2016072392A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017025019A (ja) * 2015-07-21 2017-02-02 Ｗｅｌｌ Ｓｔｏｎｅ 有限会社 アミロイドβ線維分解剤、アミロイドβの線維化に起因する疾患の治療薬・予防薬および治療用・予防用食品組成物
AU2018240774B2 (en) 2017-03-21 2023-01-12 Well Stone Co. Method for producing therapeutic agent for skin lesions, and therapeutic agent for skin lesions
TW201929877A (zh) * 2017-12-29 2019-08-01 大江生醫股份有限公司 地龍蛋白用於製造保護腦神經細胞醫藥組成物之用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5728007A (en) 1980-07-29 1982-02-15 Mitsuo Ishikura Preparation of colorless, transparent and tasteless earthworm extract
JPS59216572A (ja) 1983-05-20 1984-12-06 Yoichi Ishii ミミズ蛋白及び脂質健康食品
KR900012617A (ko) 1987-10-28 1990-09-01 요오이찌 이시이 혈전증 치료제 및 그 제조방법
JPH02215723A (ja) 1989-02-15 1990-08-28 Eimei:Kk 血圧調節剤
RU2177784C2 (ru) 1999-06-01 2002-01-10 Пермское научно-производственное объединение "Биомед" Энтеральный препарат, содержащий экстракт биомассы красного калифорнийского дождевого червя eisenia foetidae в виде таблеток "вермин"
ITRM20050045A1 (it) * 2005-02-02 2006-08-03 Consiglio Nazionale Ricerche Proteina isolata da eisenia foetida simile all'ngf umano e usi relativi.
CN1873005A (zh) * 2005-06-02 2006-12-06 中国科学院生物物理研究所 蚯蚓微管结合蛋白Tau、其编码基因及其应用
CN101095697A (zh) 2006-06-28 2008-01-02 李振国 水蛭和/或地龙分子量5800道尔顿以下的提取物
CN101543512B (zh) * 2008-03-28 2012-03-28 井石有限会社 蚯蚓干燥粉末的生产方法
KR20100137576A (ko) 2008-04-24 2010-12-30 브리스톨-마이어스 스큅 컴퍼니 알츠하이머병을 포함하는 타우-관련 질병의 치료에서의 에포틸론 ｄ의 용도
JP4886017B2 (ja) * 2009-10-13 2012-02-29 Ｗｅｌｌ Ｓｔｏｎｅ 有限会社 ミミズ乾燥粉末の製造方法
KR101198192B1 (ko) * 2011-04-11 2012-11-12 웰 스톤 유겐가이샤 지렁이 건조 분말의 제조 방법
JP4808822B1 (ja) * 2011-04-11 2011-11-02 Ｗｅｌｌ Ｓｔｏｎｅ 有限会社 ミミズ乾燥粉末の製造方法
US9060958B2 (en) 2011-07-29 2015-06-23 Well Stone Co. Tyrosinase inhibitor produced using dried earthworm powder, and method for producing same
JP5856725B2 (ja) * 2011-08-02 2016-02-10 和夫 酒井 うつ病治療用または予防用医薬組成物
CN103251884B (zh) * 2013-05-03 2015-02-18 杨文明 治疗阿尔茨海默病的中药及其制备方法和应用
CN103550537B (zh) * 2013-11-10 2014-08-06 孟晓彬 一种治疗阿尔茨海默病的中药制剂及制备方法
CN106413722B (zh) 2014-01-20 2020-08-04 井石有限会社 儿茶酚胺产生促进剂，起因于儿茶酚胺的缺乏的疾病的治疗药/预防药

Also Published As

Publication number Publication date
TW201630616A (zh) 2016-09-01
RU2742658C2 (ru) 2021-02-09
JP2016088877A (ja) 2016-05-23
KR101948913B1 (ko) 2019-02-15
US20170348357A1 (en) 2017-12-07
EP3216456A1 (en) 2017-09-13
RU2017118158A (ru) 2018-12-05
RU2017118158A3 (pt) 2019-06-06
US10576108B2 (en) 2020-03-03
WO2016072392A8 (ja) 2017-03-30
KR20170072348A (ko) 2017-06-26
AU2015344361A1 (en) 2017-06-15
WO2016072392A1 (ja) 2016-05-12
CN106794199A (zh) 2017-05-31
CN106794199B (zh) 2021-03-23
AU2015344361B2 (en) 2020-10-01
CA2964316C (en) 2024-05-14
TWI689311B (zh) 2020-04-01
PH12017500743A1 (en) 2017-10-09
US10398740B2 (en) 2019-09-03
BR112017008734B1 (pt) 2021-11-23
JP6321521B2 (ja) 2018-05-09
EP3216456A4 (en) 2018-05-09
US20190365826A1 (en) 2019-12-05
EP3216456B1 (en) 2020-09-16
CA2964316A1 (en) 2016-05-12

Similar Documents

Publication Publication Date Title
SG10201808102WA (en) Bicyclic heterocycle compounds and their uses in therapy
MX2022009155A (es) Nuevos profarmacos polimericos de la hormona del crecimiento humana (hgh).
BR112017016759A2 (pt) recipiente de plástico pré-carregado, kit, uso do recipiente de plástico pré-carregado, método para o tratamento de uma doença ou condição, método para o tratamento cosmético da pele
BR112016027024A2 (pt) polipeptídeos de ligação específica e seus usos
EA201691570A1 (ru) Фармацевтическая композиция, включающая диамино-гетероциклическое карбоксамидное соединение в качестве активного ингредиента
BR112017007138A2 (pt) composto, medicamento, métodos para reduzir proteína 4 de ligação ao retinol e para a profilaxia ou o tratamento de degeneração macular e/ou uma doença, e, uso de um composto.
BR112016015997A2 (pt) ?composições farmacêuticas que compreendem 15- hepe e métodos para tratar asma e distúrbios pulmonares com o uso das mesmas?
BR112017008734A2 (pt) acelerador de produção de proteína tau e agente preventivo ou terapêutico e composição alimentícia preventiva ou terapêutica para doenças causadas por deficiência de proteína tau
SV2017005441A (es) Antagonista de a2a de dosis baja para el tratamiento de tdah y la enfermedad de parkinson
EA201690936A1 (ru) Применение цистеамина и его производных для лечения митохондриальных заболеваний
BR112017012906A2 (pt) composição contendo extrato misturado de amora e casca de poria cocos para a prevenção, melhora ou o tratamento de distúrbios neurodegenerativos
BR112016014981A2 (pt) Acelerador de produção de catecolamina e agente preventivo e terapêutico e composição alimentícia preventiva e terapêutica para doenças causadas por deficiência de catecolamina
MX364528B (es) Witanólidos útiles para el tratamiento de enfermedades neurodegenerativas.
PH12019501820A1 (en) Pharmaceutical compositions for combination therapy
BR112017012909A2 (pt) composição contendo extrato de casca de poria cocos para a prevenção, melhora ou tratamento de distúrbios neurodegenerativos
IN2013MU03118A (pt)
PH12017501949A1 (en) Amyloid � fibril decomposing agent, and therapeutic or preventive agent and therapeutic or preventive food composition for diseases caused by amyloid � fibril formation
BR112018007213A2 (pt) composto, formulação de fragrância, métodos para melhorar, intensificar ou modificar uma formulação de fragrância e para neutralizar odor desagradável, e, produto de fragrância.
GB2550750A (en) Anthelmintic compounds
BR112015011394A2 (pt) uso de pidotimod para tratar a dermatite atópica
BR112017020008A8 (pt) Peptídeos isolados e seus fragmentos a partir do fibrinogênio para uso como fármacos, particularmente em doenças inflamatórias da pele
EP3517121A4 (en) PHARMACEUTICAL COMPOSITION COMPRISING AN EXTRACT OF PURPLE CORN FOR THE PREVENTION OR TREATMENT OF A SKIN DISEASE
MX2018009351A (es) Nuevos compuestos bioaromaticos de propinilo, composiciones farmaceuticas y cosmeticas que contienen los mismos y usos de los mismos.
TR201716203A1 (tr) Yeni umeklidinyum formülasyonları.
TH167851B (th) (s)-เพอร์ลินโดล และเกลือที่ยอมรับได้ทางเภสัชกรรมของมันสำหรับ การใช้ในยารักษาโรค

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/11/2015, OBSERVADAS AS CONDICOES LEGAIS.